Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics.
Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the
Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and
colorectal cancers. Leap has entered into a strategic collaboration with BeiGene, Ltd. for the rights to
develop DKN-01 in ...
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics.
Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the
Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and
colorectal cancers. Leap has entered into a strategic collaboration with BeiGene, Ltd. for the rights to
develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. FL-301, is a humanized monoclonal
antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.